All In Biotech

Drug Trial Radar · NCT01439984

Trial of PED-1 in Male Patients With Premature Ejaculation

A Randomized, Double-blind, Placebo-controlled, Fixed Dose, Parallel Grouped, Multi-center Clinical Study to Evaluate the Safety and Efficacy of PED-1 in Male Patients With Premature Ejaculation

Last checked: Nov 20, 2026Latest source record: Oct 3, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 159 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

159

Actual

Start

Sep 2011

Primary completion

Jun 2012

Study completion Jun 2012

Sponsor

Lead sponsor
SymyooIndustry
Sponsor type
Industry
First posted
Sep 23, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 20 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate whether PED-1 is more effective than Placebo in the treatment of premature ejaculation.

Conditions

  • Premature Ejaculation

Interventions

  • ClomipramineDrug

    Clomipramine 15 mg tablet or placebo tablet on demand for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intravaginal ejaculation latency time (IELT)(seconds)Time frame: 12 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Ewha Womans University Mokdong Hospital

    Seoul, South Korea

  • Seoul St.Marry's Hospital

    Seoul, South Korea

  • Inje University Ilsan Paik Hospital

    Goyang-si, Gyeonggi-do, South Korea

  • National Health Insurance Corporation Ilsan Hospital

    Goyang-si, Gyeonggi-do, South Korea

  • Uijeongbu St.Marry's Hospital

    Uijeongbu-si, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.